Atracurium oxalate

Section 1: Chemical Product and Company Identification

Product Name: Atracurium oxalate

CAS#: 64228-78-0

EINECS#: 264-741-3

Supplier: KINFON PHARMACHEM CO.,LTD

F4, No.5 Torch Ave, JLP Dist, Chongqing 400080, China

website: www.echemix.com     email: sales@echemix.com

Section 2: Composition and Information on Ingredients

Name                CAS #                     Synonyms

Atracurium oxalate      64228-78-0        Pentamethylene bis[1-(3,4-dimethoxybenzyl)-

3,4-dihydro-6,7-dimethoxy-1H-isoquinoline-2-propionate] dioxalate

NON-HAZARDOUS INGREDIENTS   Unassigned

Section 3: Hazards Identification

Fire and Explosion: This product is classified as non-flammable.

Health: Caution - Pharmaceutical agent.

Pharmacological effects may occur following skin absorption.

Exposure might occur via ingestion; skin; eyes.

Possible effects of overexposure in the workplace include: symptoms of hypersensitivity

(such as skin rash, hives, itching, and difficulty breathing).

Health effects information is based on hazards of components.

Environment: No information is available about the potential of this product to produce adverse

environmental effects.

Section 4: First Aid Measures

Ingestion: Never attempt to induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. If the exposed subject is fully conscious, give plenty of water to drink. Obtain medical attention.

Inhalation: Physical form suggests that risk of inhalation exposure is negligible.

Skin Contact: Using appropriate personal protective equipment, remove contaminated clothing and flush

exposed area with large amounts of water. Obtain medical attention if skin reaction occurs, which may be immediate or delayed.

Eye Contact: Wash immediately with clean and gently flowing water. Continue for at least 15 minutes.

Obtain medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment: Medical treatment in cases of overexposure should be treated as an overdose of neuromuscular blocking agent. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre.

Medical Conditions Caused or Aggravated by Exposure:

Refer to prescribing information for detailed description of medical conditions caused by or aggravated by overexposure to this product.

Section 5: Fire and Explosion Data

Fire and Explosion Hazards: Not expected for the product, although the packaging is combustible.

Extinguishing Media: No special requirements needed

Special Firefighting Procedures: For single units (packages): No special requirements needed. For larger amounts (multiplepackages/pallets) of product: Since toxic, corrosive or flammable vapours might be evolved from fires involving this product and associated packaging, self contained breathing

apparatus and full protective equipment are recommended for firefighters. If possible, contain and collect firefighting water for later disposal.

Hazardous Combustion Products: Toxic, corrosive or flammable thermal decomposition products are expected when the product is exposed to fire.

Section 6: Accidental Release Measures

Personal precautions: Wear protective clothing and equipment consistent with the degree of hazard.

Environmental precautions: For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.

Methods for cleaning up: Collect and place it in a suitable, properly labelled container for recovery or disposal.

Decontamination Procedures: No specific decontamination or detoxification procedures have been identified for this product.

Section 7: Handling and Storage

Handling:

No special control measures required for the normal handling of this product. Normal room ventilation is expected to be adequate for routine handling of this product.

Storage

No storage requirements necessary for occupational hazards.   Follow product information storage instructions to maintain efficacy.

Section 8: Exposure Controls/Personal Protection

Eye protection: Wear approved safety glasses with side shields if eye contact is possible.

Other Equipment or Procedures: Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling. An eye wash station should be available.

Section 9: Physical and Chemical Properties

Appearance

Form crystalline

Colour: white or light yellow

Safety data

pH no data available

Melting point 185-194°C

Boiling point 916.8°C at 760 mmHg

Flash point508.3°C

Ignition temperature no data available

Lower explosion limit no data available

Upper explosion limit no data available

Water solubility no data available

Section 10: Stability and Reactivity Data

Storage stability

This product is expected to be stable..

Conditions to Avoid: None for normal handling of this product.

Section 11: Toxicological Information

Pharmacological Effects: This product contains active ingredient(s) with the following activity: a muscle relaxant for use during anaesthesia.

Target Organ Effects: No specific target organ effects have been identified.

Oral Toxicity: Not expected to be toxic following ingestion.

Inhalation Toxicity: No studies have been conducted

Skin Effects: Pharmacological effects may occur following skin absorption. Irritation is not expected following direct contact.

Eye Effects: Direct contact with eyes might produce evidence of pharmacological effects. Irritation is not expected following direct contact with eyes.

Sensitisation: Allergic skin reactions might occur following dermal exposure.

Genetic Toxicity: Not expected to be genotoxic under occupational exposure conditions.

Carcinogenicity: No components are listed as carcinogens by GSK, IARC, NTP or US OSHA.

Reproductive Effects: Not expected to produce adverse effects on fert ility or development   under occupational exposure conditions.

Other Adverse Effects：None known for occupational exposure.

Section 12: Ecological Information

Ecotoxicity: This material contains an active pharmaceutical ingredient that may be harmful to aquatic organisms.

Activated Sludge Respiration: This material contains an active pharmaceutical ingredient that is not

toxic to activated sludge microorganisms.

Solubility: This material contains an active pharmaceutical ingredient that for environmental fate predictions has solubility in water.

Section 13: Disposal Considerations
Collect for recycling or recovery if possible. The disposal method for rejected products/returned goods must ensure that they cannot be re-sold or re-used.

Regulatory Requirements: Observe all local and national regulations when disposing of this product.

Section 14: Transport Information

UN Classification and Labe lling:

Transport Information: Transportation and shipping of this product is not restricted. It has no known,

significant hazards requiring special packaging or labelling for air, maritime, US or European ground transport purposes.

Section 15: Other Regulatory Information

EU Classification and Labe lling: Exempt from requirements of EU Dangerous Preparations directive - product regulated as a medicinal product, cosmetic product or medical device

US OSHA Standard (29 CFR Part 1910.1200):

Classification: This product is classified as hazardous according to the OSHA Hazard Communication

Standard.

Section 16: Other Information

References: Not available.

Other Special Considerations: Not available.

All information and instructions provided in this Material Safety Data Sheet (MSDS) are based on the current state of scientific and technical knowledge. And above information is only for reference.